Experiments

Searchable full-text extractions: founding hypothesis, core claims, experimental setups, key results and statistics — pulled out of each paper as structure. Search a cell line, an assay or an entity (e.g. HUH7) and find every paper that worked with it. This corpus stands on its own: most entries carry no reproduction assessment (yet).

• MicroRNA profiling of BRCA1/2 mutation-carrying and non-mutation-carrying high-grade serous carcinomas of ovary.

  PMID 19798417 · PMC2749450 · PloS one · 2009 · 7 claims · 7 setups

  Full-text index only

  High grade serous carcinomas with and without BRCA1/2 abnormalities show very similar miRNA expression profiles, with no clear clustering separation by BRCA1/2 status

  high ovarian mir-29a mirna unsupervised significance

• Dynamic changes of the immune microenvironment in ovarian cancer following neoadjuvant chemotherapy.

  PMID 41872134 · PMC13039919 · Cell death discovery · 2026 · 8 claims · 8 setups

  Full-text index only

  Prostaglandin-mediated immunosuppressive microenvironment formation is a critical contributor to chemotherapy resistance following cisplatin treatment

  high-grade hgsoc bone bmdms scrna-seq cell-cell tensor

• Robust and efficient annotation of cell states through gene signature scoring.

  PMID 41708334 · PMC12951948 · Genome research · 2026 · 8 claims · 8 setups

  Full-text index only

  Established scoring methods (Seurat, SCANPY, UCell, JASMINE) fail to provide robust and comparable score distributions across diverse signatures and experimental conditions, precluding accurate unsupervised cell-state annotation.

  pbmc colorectal esophageal crc scrna-seq cross-implementation signature

• Mutation of ERBB2 provides a novel alternative mechanism for the ubiquitous activation of RAS-MAPK in ovarian serous low malignant potential tumors.

  PMID 19010816 · PMC6953412 · Molecular cancer research : MCR · 2008 · 8 claims · 8 setups

  Full-text index only

  Activating RAS-MAPK pathway mutations are present in >70% of serous LMP tumors versus ~12.5% of serous ovarian carcinomas

  serous same lmp braf-mutant gene hotspot erbb2